Afatinib Recruiting Phase 3 Trials for Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01427478Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck